B Cell Lymphoma
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...
News
R-CHOP looks viable as first line in follicular lymphoma
Long-term follow-up of a randomized trial showed durable efficacy of R-CHOP with no increase in histological transformation or secondary cancers...
News
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
Conference Coverage
CLL: The initial work-up
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
News
FDA puts selinexor on fast track for DLBCL
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.
News
Selinexor on fast track for DLBCL
The U.S.
News
Combo appears safe, active in rel/ref NHL
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or...
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...